Results 51 to 60 of about 3,371 (214)

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System [PDF]

, 2022
BACKGROUND: The dopaminergic partial agonism of the so-called third-generation antipsychotics (TGAs; aripiprazole, brexpiprazole, cariprazine) is hypothesized to cause impulse control disorders (ICDs).
De Ponti F., Fusaroli M., Giunchi V., Menchetti M., Poluzzi E., Raschi E., Rimondini Giorgini R.   +6 more
core   +1 more source

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?

Frontiers in Psychiatry, 2022
Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug ...
Pavel Mohr, Pavel Mohr, Jirí Masopust, Miloslav Kopeček, Miloslav Kopeček   +4 more
doaj   +1 more source

The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices [PDF]

, 2019
Background and purpose: Gamma oscillations are fast rhythmic fluctuations of neuronal network activity ranging from 30 to 90 Hz that establish a precise temporal background for cognitive processes such as perception, sensory processing, learning, and ...
Adham, Nika, Gerevich, Zoltan, Kiss, Béla, Kulisch, Christoph, Lemercier, Clement E., Lendvai, Balázs, Meier, Maria A.   +6 more
core   +1 more source

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park, Yitian Zhou, Volker M. Lauschke   +2 more
wiley   +1 more source

Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
This graphical summary illustrates the efficacy and safety of brexpiprazole (2–4 mg) in patients with schizophrenia. The meta‐analysis demonstrates significant improvement in clinical outcomes, with reductions in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression ‐ Severity scale (CGI‐S) scores, indicating better symptom ...
Sher Bano, Aashan Ahmad, Abdul Haseeb Mohammed, Ismailova Rushana Nurbekovna, Saja Saad, Noor Fatima, Muhammad Bilal Akbar, Zainab Salahuddin, Sadikun Nabi, Mohammad Mustafa Ababneh, Laiba Ajmal, Sidra Hariss, Hiba Manaf, Farah Saleh, Raouf Khan   +14 more
wiley   +1 more source

SPLICEIT Fluorescent Sensor for Integrating Dopamine Release with Cellular Resolution

Angewandte Chemie, Volume 137, Issue 33, August 11, 2025.
“Single‐chain protein‐based ligand indication through a chimerically‐engineered integrator tool” (SPLICEIT) is a G‐protein coupled receptor‐based sensor design that leaves a permanent fluorescent mark. We show dopamine detection in primary cultured neurons with a fourfold signal increase normalized to an mCherry (mCh) marker.
Steven M. Havens, Brian Georgis, Jian Weng, Jessi Rodriguez, Hannah Rivett, Shadan Alrawi, Peng Li, Wenjing Wang   +7 more
wiley   +2 more sources

Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity [PDF]

, 2018
Aberrant glutamatergic, dopaminergic, and GABAergic neurotransmission has been implicated in schizophrenia. Cariprazine reverses the behavioral effects observed in the rat phencyclidine (PCP)-induced model of schizophrenia; however, little is known about
Adham, N, Gyertyán, István, Ichinose, F, Kehr, J, Kiss, B, Yoshitake, S, Yoshitake, T   +6 more
core   +1 more source

Clinical pharmacology consultations and their implementation in clinical decision making

British Journal of Clinical Pharmacology, Volume 92, Issue 4, Page 1069-1077, April 2026.
Aims One of the key roles of clinical pharmacologists is to work as consultants for other medical specialties. We wanted to investigate the characteristics of clinical pharmacology consultations, compare the types of consultations from different specialties, and evaluate how well the recommendations given were followed.
Mirjam Kauppila, Janne T. Backman, Outi Lapatto‐Reiniluoto   +2 more
wiley   +1 more source

A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia

Frontiers in Psychiatry
Management of negative symptoms is one of the most challenging and important unmet needs of schizophrenia treatment. Negative symptoms together with positive symptoms result in significant psychosocial impairment and poor quality of life.
Panneer Selvan, Prashant Devkare, Arthik Shetty, Shruti Dharmadhikari, Chintan Khandhedia, Amey Mane, Suyog Mehta, Chittaranjan Andrade   +7 more
doaj   +1 more source

Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine

Pharmacopsychiatry
Abstract IntroductionCariprazine is an atypical dopamine receptor partial agonist antipsychotic available in the form of capsules. Although capsules are one of the most desirable routes of administration, there are certain situations (e.
Meszár, Viktória, Magyar, Gabriella, Pásztor, Gabriella Mészárosné, Szatmári, Balázs, Péter, Krisztina, Marton, Lívia, Dombi, Zsófia B., Barabássy, Ágota   +7 more
openaire   +2 more sources